S. 3921 (111th): Ethical Pathway Act of 2010

Introduced:
Sep 29, 2010 (111th Congress, 2009–2010)
Status:
Died (Referred to Committee)
Sponsor
Bernard “Bernie” Sanders
Senator from Vermont
Party
Independent
Text
Read Text »
Last Updated
Sep 29, 2010
Length
10 pages
Related Bills
S. 3506 (112th) was a re-introduction of this bill in a later Congress.

Referred to Committee
Last Action: Aug 02, 2012

 
Status

This bill was introduced on September 29, 2010, in a previous session of Congress, but was not enacted.

Progress
Introduced Sep 29, 2010
Referred to Committee Sep 29, 2010
 
Full Title

A bill to ensure that rules for the approval of pharmaceutical and biological products do not require violations of medical ethics in the testing of products in humans and vertebrate animals.

Summary

No summaries available.

Cosponsors
none
Committees

Senate Health, Education, Labor, and Pensions

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

S. stands for Senate bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


9/29/2010--Introduced.
Ethical Pathway Act of 2010 - Directs the Secretary of Health and Human Services (HHS), acting through the Commissioner of Food and Drugs (FDA), to establish a mechanism by which an applicant for an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, for license of a biosimilar biological product submitted under the Public Health Service Act, or for a license to sell in the United States a drug that has been approved for marketing in a foreign country may request a cost-sharing arrangement under which the applicant and the holders of relevant applications or licenses shall make every effort to ensure that any regulatory test data and results of clinical investigations involving humans and vertebrate animals conducted regarding such applications or licenses is shared, including the regulatory test data necessary to obtain marketing approval from the Secretary.
Permits such applicant to request such arrangement if, but for the arrangement:
(1) the applicant would be required to conduct clinical investigations involving human subjects that violate Article 20 of the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects in order to obtain the Secretary's approval or licensure; or
(2) the duplication of the clinical investigations required for such application would violate other applicable ethical standards concerning the testing of products on humans or other vertebrate animals.
Sets forth provisions regarding:
(1) the responsibility of an applicant that intends to perform clinical investigations involving humans or vertebrate animals to verify that those investigations have not been performed or initiated by another person,
(2) agreement between an applicant and the holders of the relevant applications or licenses on a fee that is reasonable and fair that permits the applicant to rely upon information from such regulatory test data, and
(3) procedures to determine such fee or required payment when such parties fail to reach such an agreement.
Requires the fee for reliance on such regulatory test data to be determined after considering:
(1) the actual out-of-pocket costs of the applicable clinical investigations;
(2) the risks of the investigations;
(3) any federal grants, tax credits, or other subsidies;
(4) the expected share of the global market for the product involved; and
(5) the amount of time the holders of the relevant applications or licenses have benefited from exclusive rights and the cumulative revenue earned on the products that relied upon the data at issue.
Directs the Secretary to adopt procedures and rules under which sufficient information about costs and fees will be made public.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of S. 3921 (111th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus